Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook

Core Viewpoint - Halozyme Therapeutics, Inc. is raising its full year 2024 financial guidance and updating its 5-year financial outlook due to the grant of a new European patent covering its ENHANZE® rHuPH20 product, which is expected to enhance its revenue streams and protect royalty rates until March 6, 2029 [1][8][16]. Financial Guidance - Total revenue is projected to be between $935 million and $1,015 million, indicating a growth of 13% to 22% compared to 2023 [4][18]. - Royalty revenue is expected to range from $520 million to $555 million, reflecting a growth of 16% to 24% over 2023 [4][18]. - Adjusted EBITDA is forecasted to be between $555 million and $615 million, representing a growth of 30% to 44% compared to 2023 [4][18]. - Non-GAAP diluted earnings per share are anticipated to be between $3.65 and $4.05, showing a growth of 32% to 46% over 2023 [4][18]. Company Overview - Halozyme is a biopharmaceutical company focused on improving patient experiences through its ENHANZE® drug delivery technology, which facilitates subcutaneous delivery of drugs [3][12]. - The company has impacted over 800,000 patients globally and has licensed its technology to major pharmaceutical companies including Roche, Takeda, and Pfizer [3][12]. - Halozyme's headquarters is located in San Diego, CA, with additional offices in Ewing, NJ, and Minnetonka, MN [5].